The Taibo® Sildenafil Citrate Orally Disintegrating Tablets (50mg), which is our company's new dosage form and deemed to have passed the consistency evaluation, was recently approved for marketing.
MoreOn April 28, 2011, C&O announced that it has been authorized by Shionogi & Co., Ltd., a Japanese pharmaceutical company, to be the exclusive distributor of Flumarin®, an antibiotic of oxacephalosporins for injection, in China.
MoreIn March 2011, the high standard edaravone raw materials and injection developed by C&O was approved by SFDA. Edaravone is a neuroprotective agent, used to improve neurological symptoms, activities of daily living and functional impairment due to acu
MoreSumitomo became the strategic shareholder with shareholding of 29% held in C&O. C&O Board of Directors has been restructured and Sumitomo Corporation will appoint three directors to the C&O Board.
MoreThe Chinese government has recently included four new drug projects being developed by C&O in the major scientific and technological projects for “major new drug initiation”, the first program established by the Chinese government in the 11th Five-Ye
More
Address5/F, Jihao Building, 1086 Shennan East Road, Luohu District, Shenzhen
Adverse drug reactions / Event feedback hotline025-6816 1304
Adverse drug reactions / Event feedback mailGVP@changao.com
Official WeChat account 
Mobile page